Alnylam Pharmaceuticals Inc (ALNY) — Capital Reinvestment Ratio
Alnylam Pharmaceuticals Inc (ALNY) has a Capital Reinvestment Ratio of 0.14x as of December 2025, meaning it reinvests 0% of its operating cash flow ($163.56 Million) in capital expenditures ($23.29 Million). See how much free cash does Alnylam Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Alnylam Pharmaceuticals Inc Capital Reinvestment Ratio (2007–2025)
This chart tracks Alnylam Pharmaceuticals Inc's Capital Reinvestment Ratio across 4 annual periods.
Annual Capital Reinvestment Ratio for Alnylam Pharmaceuticals Inc (2007–2025)
Year-by-year Capital Reinvestment Ratio for Alnylam Pharmaceuticals Inc from 2007 to 2025. For live market cap and broader valuation context, see Alnylam Pharmaceuticals Inc stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | $524.08 Million | $58.70 Million | ▼ -81.2% |
| 2023 | 0.60x | $104.16 Million | $62.21 Million | ▲ +263.4% |
| 2008 | 0.16x | $65.49 Million | $10.76 Million | ▲ +314.7% |
| 2007 | 0.04x | $196.52 Million | $7.79 Million | — |